Research programme: kinase inhibitors - Plexxikon

Drug Profile

Research programme: kinase inhibitors - Plexxikon

Alternative Names: Omni-Raf inhibitors - Plexxikon; PLX-FK1; PLX4720

Latest Information Update: 15 Apr 2016

Price : $50

At a glance

  • Originator Plexxikon
  • Developer OncoSec Medical; Plexxikon
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony stimulating factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto-oncogene protein b-raf modulators; Raf kinase inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cancer; Inflammation; Malignant melanoma; Multiple sclerosis; Polycystic kidney disease

Most Recent Events

  • 15 Apr 2016 Preclinical development for Multiple sclerosis and Alzheimer's disease is ongoing in USA
  • 18 Nov 2014 Plexxikon and OncoSec Medical enter into a preclinical collaboration to evaluate combination immunotherapy for Cancer, including malignant melanoma
  • 18 Nov 2014 Preclinical trials in Malignant melanoma (Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top